267 related articles for article (PubMed ID: 18268076)
21. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.
Engtrakul JJ; Foti RS; Strelevitz TJ; Fisher MB
Drug Metab Dispos; 2005 Nov; 33(11):1621-7. PubMed ID: 16049128
[TBL] [Abstract][Full Text] [Related]
22. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
23. In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization.
Yergey JA; Trimble LA; Silva J; Chauret N; Li C; Therien M; Grimm E; Nicoll-Griffith DA
Drug Metab Dispos; 2001 May; 29(5):638-44. PubMed ID: 11302928
[TBL] [Abstract][Full Text] [Related]
24. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
Kazmi F; Barbara JE; Yerino P; Parkinson A
Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
[TBL] [Abstract][Full Text] [Related]
25. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
[TBL] [Abstract][Full Text] [Related]
26. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.
Koeberle A; Siemoneit U; Bühring U; Northoff H; Laufer S; Albrecht W; Werz O
J Pharmacol Exp Ther; 2008 Sep; 326(3):975-82. PubMed ID: 18550688
[TBL] [Abstract][Full Text] [Related]
27. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases.
Tong Z; Li H; Goljer I; McConnell O; Chandrasekaran A
Drug Metab Dispos; 2007 Dec; 35(12):2203-10. PubMed ID: 17875670
[TBL] [Abstract][Full Text] [Related]
28. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function.
Rotondo S; Dell'Elba G; Krauze-Brzósko K; Manarini S; Martelli N; Pecce R; Evangelista V; Cerletti C
Eur J Pharmacol; 2002 Oct; 453(1):131-9. PubMed ID: 12393068
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies.
Gunduz M; Argikar UA; Baeschlin D; Ferreira S; Hosagrahara V; Harriman S
Drug Metab Dispos; 2010 Mar; 38(3):361-7. PubMed ID: 20008038
[TBL] [Abstract][Full Text] [Related]
30. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
[TBL] [Abstract][Full Text] [Related]
31. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.
Mohammed A; Janakiram NB; Li Q; Choi CI; Zhang Y; Steele VE; Rao CV
Cancer Prev Res (Phila); 2011 Dec; 4(12):2015-26. PubMed ID: 21885812
[TBL] [Abstract][Full Text] [Related]
33. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
Hanioka N; Naito T; Narimatsu S
Chemosphere; 2008 Dec; 74(1):33-6. PubMed ID: 18990428
[TBL] [Abstract][Full Text] [Related]
34. UDP-glucuronosyltransferase isoforms catalyzing glucuronidation of hydroxy-polychlorinated biphenyls in rat.
Daidoji T; Gozu K; Iwano H; Inoue H; Yokota H
Drug Metab Dispos; 2005 Oct; 33(10):1466-76. PubMed ID: 16006569
[TBL] [Abstract][Full Text] [Related]
35. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
36. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
Gaganis P; Miners JO; Knights KM
Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
[TBL] [Abstract][Full Text] [Related]
37. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.
Kerdpin O; Knights KM; Elliot DJ; Miners JO
Biochem Pharmacol; 2008 Jul; 76(2):249-57. PubMed ID: 18541222
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.
Uchiyama M; Koda H; Fischer T; Mueller J; Yamamura N; Oguchi M; Iwabuchi H; Okazaki O; Izumi T
Drug Metab Dispos; 2011 Jul; 39(7):1311-9. PubMed ID: 21511943
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
Gay RE; Neidhart M; Pataky F; Tries S; Laufer S; Gay S
J Rheumatol; 2001 Sep; 28(9):2060-5. PubMed ID: 11550975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
